Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Enoxaparin for VTE prophylaxis after pulmonary cancer surgery
ChiCTR2000036790Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in venous thromboembolism (VTE) and bronchial carcinoma comparing Rivaroxaban group with Enoxaparin group (2 arms). Primary endpoint: VTE incidence. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000036790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036790.